Description: <b>Glutathione</b> = GSH (reduced form)</br>
Oxidized glutathione = GSSG</br>
GSH/GSSG ratio = key indicator of cellular redox state</br>
</br>
-Neutralizes H₂O₂ and lipid peroxides</br>
-Maintains redox homeostasis</br>
</br>
Most cancers show:</br>
-Elevated GSH levels</br>
-Increased GSH synthesis and recycling</br>
-High GSH/GSSG ratio</br>
</br>
This supports:</br>
-Survival under oxidative stress</br>
-Resistance to chemotherapy and radiation</br>
-Detoxification of drugs (e.g., irinotecan, cisplatin)</br>
-Cancer cells often develop a “GSH addiction”.</br>
</br>
<pre>
Natural Products Affecting GSH
Compound Effect
Curcumin ↓ GSH in cancer cells
Sulforaphane Transient NRF2 activation → later depletion
Resveratrol Disrupts GSH recycling
Quercetin Consumes GSH during detox
Selenium compounds Dose-dependent: support GPX or induce redox stress
High-dose Vitamin C Depletes GSH via ROS overload
</pre>
</br>
**** Glutathione is more applicable as a Target/pathway ****** <br>
<p><b>Glutathione</b> — an endogenous sulfur-containing tripeptide composed of glutamate, cysteine, and glycine and the principal low-molecular-weight intracellular thiol antioxidant. Reduced glutathione is abbreviated GSH; its oxidized disulfide form is GSSG, and the GSH/GSSG ratio is a major indicator of cellular redox status. Glutathione functions as a cofactor for glutathione peroxidases, participates in electrophile and drug conjugation through glutathione S-transferases, maintains protein thiol redox state, and supports mitochondrial redox homeostasis. In cancer, glutathione has a strongly context-dependent and frequently tumor-protective role: many tumors increase GSH synthesis, recycling, or utilization to tolerate oxidative stress and resist chemotherapy, radiotherapy, and ferroptosis. Consequently, therapeutic cancer research more often targets GSH depletion or the upstream system xc−/GCLC/GSH/GPX4 axis than administers GSH as an anticancer agent.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Intracellular redox buffering through the GSH/GSSG couple and glutathione-peroxidase-dependent detoxification of hydrogen peroxide and organic peroxides.</li>
<li>Suppression of ferroptosis through the GSH-dependent activity of GPX4, which reduces membrane phospholipid hydroperoxides.</li>
<li>Detoxification of electrophilic xenobiotics and anticancer drugs through glutathione S-transferase-mediated conjugation, contributing to treatment resistance in some cancers.</li>
<li>Maintenance of mitochondrial redox homeostasis and protection against mitochondrial permeability transition, oxidative injury, and apoptosis.</li>
<li>Protein S-glutathionylation and deglutathionylation, which regulate redox-sensitive signaling, protein activity, stress responses, proliferation, and cell-death pathways.</li>
<li>NRF2-regulated glutathione synthesis and recycling is an important upstream control system; persistent NRF2 activation in some tumors increases GSH-dependent antioxidant capacity and treatment resistance.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral glutathione is partially degraded in the gastrointestinal tract, but controlled human studies demonstrate that sustained oral dosing can increase blood and cellular glutathione stores. A 6-month randomized trial using 250 or 1,000 mg/day increased GSH in several blood compartments, indicating that oral bioavailability is not negligible. The magnitude of tissue exposure is nevertheless formulation-, dose-, duration-, and tissue-dependent. Direct delivery of intact GSH into tumors or the brain is substantially less predictable than changes in peripheral glutathione status.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many mechanistic cancer experiments manipulate intracellular GSH genetically or pharmacologically rather than reproducing concentrations achievable through oral supplementation. Extracellular millimolar GSH concentrations sometimes used experimentally should therefore not be interpreted as equivalent to oral supplementation. The biologically relevant variable in cancer is generally intracellular GSH synthesis, recycling, compartmentalization, and GPX4 availability rather than plasma GSH alone.</p>
<p><b>Clinical evidence status:</b> Glutathione is not an established anticancer treatment. Human oncology evidence is primarily adjunctive, including older trials of intravenous reduced glutathione intended to reduce platinum-associated neurotoxicity or other chemotherapy toxicity; some studies reported neuroprotection without obvious loss of tumor response, but this does not establish anticancer efficacy. A contemporary trial is investigating GSH with anti-PD-1-based therapy in non-small-cell lung cancer, so direct anticancer use remains investigational. In Canada, oral glutathione is available in licensed Natural Health Products with antioxidant-related claims, not cancer-treatment indications. Injectable compounded glutathione requires additional caution because sterility and endotoxin contamination can produce serious adverse events.</p>
<h3>Glutathione Cancer-Relevant Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>GSH/GSSG Redox Buffering</td>
<td>↑ frequently</td>
<td>↑ protective</td>
<td>↓ ROS and oxidative damage</td>
<td>High intracellular GSH frequently supports tumor survival under constitutive oxidative stress. GSH depletion generally produces the therapeutically favorable direction in cancer cells.</td>
</tr>
<tr>
<td>2</td>
<td>GSH GPX4 Ferroptosis Defense</td>
<td>↑ ferroptosis resistance</td>
<td>↑ membrane protection</td>
<td>↓ phospholipid hydroperoxides and ↓ ferroptosis</td>
<td>GSH is an obligatory reducing substrate for GPX4. Depletion of GSH or inhibition of its synthesis sensitizes many cancer models to ferroptosis.</td>
</tr>
<tr>
<td>3</td>
<td>System xc− GCLC GSH Synthesis</td>
<td>↑ frequently</td>
<td>↔ physiological regulation</td>
<td>↑ cysteine-dependent antioxidant capacity</td>
<td>SLC7A11-mediated cystine uptake and GCLC-dependent synthesis maintain tumor GSH pools and are major therapeutic targets upstream of GSH.</td>
</tr>
<tr>
<td>4</td>
<td>Glutathione S Transferase Drug Detoxification</td>
<td>↑ resistance (context-dependent)</td>
<td>↑ detoxification</td>
<td>↑ conjugation and elimination of electrophilic compounds</td>
<td>GSH-dependent GST pathways can reduce intracellular activity of platinum compounds and other electrophilic drugs and contribute to multidrug resistance.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial Redox and MPTP</td>
<td>↓ mitochondrial ROS and ↓ apoptosis</td>
<td>↓ mitochondrial injury</td>
<td>Maintains mitochondrial thiol and peroxide homeostasis</td>
<td>Loss of mitochondrial GSH promotes mitochondrial oxidative stress, permeability-transition susceptibility, cytochrome-c release, and cell death.</td>
</tr>
<tr>
<td>6</td>
<td>ROS Modulation</td>
<td>↓ ROS</td>
<td>↓ ROS</td>
<td>Antioxidant buffering</td>
<td>In cancer this direction can be unfavorable when ROS is required for chemotherapy, radiotherapy, or ferroptotic killing. GSH depletion instead causes ↑ ROS and treatment sensitization.</td>
</tr>
<tr>
<td>7</td>
<td>NRF2 GSH Antioxidant Program</td>
<td>↑ GSH downstream of NRF2</td>
<td>↑ cytoprotection</td>
<td>↑ GCLC GCLM SLC7A11 and antioxidant capacity</td>
<td>NRF2 is upstream rather than activated directly by GSH. Constitutive NRF2 signaling can generate high-GSH, therapy-resistant tumor phenotypes.</td>
</tr>
<tr>
<td>8</td>
<td>Protein S Glutathionylation</td>
<td>↔ context-dependent</td>
<td>↔ physiological regulation</td>
<td>Redox regulation of signaling proteins</td>
<td>Reversible S-glutathionylation can alter enzymes, transcription factors, cytoskeletal proteins, and apoptotic regulators; direction varies by target and redox state.</td>
</tr>
<tr>
<td>9</td>
<td>Chemosensitization</td>
<td>↓ with GSH elevation; ↑ with GSH depletion</td>
<td>↔</td>
<td>Modulates chemotherapy response</td>
<td>High tumor GSH is a recognized resistance mechanism. Experimental depletion using synthesis or cystine-transport inhibition can restore drug sensitivity in several models.</td>
</tr>
<tr>
<td>10</td>
<td>Radiosensitization</td>
<td>↓ with GSH elevation; ↑ with GSH depletion</td>
<td>↓ radiation injury with higher GSH</td>
<td>Modulates radiation-induced oxidative damage</td>
<td>Because radiation partially depends on ROS-mediated damage, increased tumor antioxidant capacity may reduce radiosensitivity, whereas GSH depletion can enhance oxidative injury.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Context-dependent tumor protection</td>
<td>Potential cytoprotection</td>
<td>Supplementation is not equivalent to tumor GSH depletion</td>
<td>Oral GSH can increase systemic GSH, but tumor exposure and therapeutic direction are unpredictable. Direct supplementation should not be interpreted as an anticancer strategy; concomitant use with ROS-dependent therapy requires clinical context. Injectable compounded products also carry sterility and endotoxin risks.</td>
</tr>
</tbody>
</table>
<br><br>
<p><b>Alzheimer’s disease relevance:</b> Brain glutathione is mechanistically relevant to Alzheimer’s disease because GSH is a major neuronal and glial antioxidant and human magnetic-resonance spectroscopy studies have demonstrated reduced hippocampal GSH in mild cognitive impairment and Alzheimer’s disease, with lower levels associated with cognitive impairment. The therapeutic rationale is therefore restoration of deficient antioxidant capacity rather than suppression of GSH. However, direct oral or intravenous glutathione has not been established as a disease-modifying AD therapy, and evidence for specifically increasing brain GSH with standard oral GSH remains substantially weaker than evidence showing an association between endogenous brain GSH depletion and AD.</p>
<p><b>Clinical evidence status:</b> Human evidence is primarily biomarker and observational evidence demonstrating brain GSH depletion, supported by mechanistic and preclinical studies. Direct glutathione supplementation lacks convincing randomized clinical evidence for cognitive or disease-modifying benefit in AD. Strategies using GSH precursors such as cysteine or N-acetylcysteine are related but should be treated separately from direct glutathione supplementation.</p>
<h3>Glutathione Alzheimer’s-Relevant Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>AD Modulation</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Brain GSH Redox Capacity</td>
<td>↓ in AD; restoration desirable</td>
<td>↓ oxidative stress</td>
<td>Human MRS studies show hippocampal GSH depletion in MCI and AD and an association with cognitive impairment.</td>
</tr>
<tr>
<td>2</td>
<td>Glutathione Peroxidase Defense</td>
<td>↑ desirable</td>
<td>↓ hydrogen peroxide and lipid peroxide accumulation</td>
<td>GSH supplies reducing equivalents to glutathione peroxidases and is central to neuronal peroxide detoxification.</td>
</tr>
<tr>
<td>3</td>
<td>Lipid Peroxidation and Ferroptotic Stress</td>
<td>↓ desirable</td>
<td>Protects neuronal membranes</td>
<td>Low GSH combined with elevated brain iron provides a plausible environment for lipid peroxidation and ferroptotic stress in AD.</td>
</tr>
<tr>
<td>4</td>
<td>Mitochondrial Redox Homeostasis</td>
<td>↑ desirable</td>
<td>↓ mitochondrial oxidative injury</td>
<td>Mitochondrial GSH supports respiratory-chain redox stability and limits peroxide-driven mitochondrial dysfunction.</td>
</tr>
<tr>
<td>5</td>
<td>Neuroinflammatory Oxidative Signaling</td>
<td>↓ indirectly</td>
<td>Reduced redox-sensitive inflammatory signaling</td>
<td>Restoring GSH can reduce oxidative amplification of inflammatory pathways, although direct clinical evidence for GSH treatment in AD remains insufficient.</td>
</tr>
<tr>
<td>6</td>
<td>Clinical Translation Constraint</td>
<td>Uncertain brain delivery</td>
<td>Limits direct therapeutic interpretation</td>
<td>Peripheral increases in GSH after oral supplementation do not establish proportional increases in neuronal or hippocampal GSH. No established disease-modifying AD indication exists.</td>
</tr>
</tbody>
</table>